Cardiovascular effects of HAART in infants and children of HIV-infected mothers

Karolina M. Zareba, Jill E. Lavigne, Steven E Lipshultz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Over the past decade, the course of human immunodeficiency virus (HIV) infection has been markedly altered by highly active antiretroviral therapy (HAART). As advances in early diagnosis and aggressive therapy, as well as better supportive care, become available to more HIV-infected patients, survival is being prolonged and more patients are experiencing cardiac abnormalities. Cardiovascular manifestations of pediatric HIV infection have especially proven to be an ongoing challenge to practicing physicians, who face cardiac abnormalities ranging from asymptomatic cardiomyopathy to severe heart failure. Antiretroviral therapy has substantially decreased vertical transmission of HIV; however, studies of adults receiving HAART have found increased peripheral and coronary artery disease. Children exposed to this therapy in utero are thus at an increased risk for toxicity and cardiac abnormalities, regardless of their HIV status. Preliminary studies have reported complications including lactic acidosis and mitochondrial toxicity, as well as cardiomyopathy. Further studies are needed to explore the long-term effects and possible toxicities of prophylactic antiretroviral therapy on infants born to HIV-infected mothers.

Original languageEnglish
Pages (from-to)271-279
Number of pages9
JournalCardiovascular Toxicology
Volume4
Issue number3
DOIs
StatePublished - Oct 29 2004

Fingerprint

Highly Active Antiretroviral Therapy
Viruses
Mothers
HIV
Toxicity
Virus Diseases
Cardiomyopathies
Lactic Acidosis
Pediatrics
Peripheral Arterial Disease
Therapeutics
Coronary Artery Disease
Early Diagnosis
Heart Failure
Physicians
Survival

Keywords

  • AIDS
  • Cardiomyopathy
  • Dyslipidemia
  • HAART
  • HIV
  • Mitochondrial toxicity
  • Prophylactic antiretroviral therapy.

ASJC Scopus subject areas

  • Toxicology
  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular effects of HAART in infants and children of HIV-infected mothers. / Zareba, Karolina M.; Lavigne, Jill E.; Lipshultz, Steven E.

In: Cardiovascular Toxicology, Vol. 4, No. 3, 29.10.2004, p. 271-279.

Research output: Contribution to journalArticle

Zareba, Karolina M. ; Lavigne, Jill E. ; Lipshultz, Steven E. / Cardiovascular effects of HAART in infants and children of HIV-infected mothers. In: Cardiovascular Toxicology. 2004 ; Vol. 4, No. 3. pp. 271-279.
@article{88e49c4e995e4637911049adca996af0,
title = "Cardiovascular effects of HAART in infants and children of HIV-infected mothers",
abstract = "Over the past decade, the course of human immunodeficiency virus (HIV) infection has been markedly altered by highly active antiretroviral therapy (HAART). As advances in early diagnosis and aggressive therapy, as well as better supportive care, become available to more HIV-infected patients, survival is being prolonged and more patients are experiencing cardiac abnormalities. Cardiovascular manifestations of pediatric HIV infection have especially proven to be an ongoing challenge to practicing physicians, who face cardiac abnormalities ranging from asymptomatic cardiomyopathy to severe heart failure. Antiretroviral therapy has substantially decreased vertical transmission of HIV; however, studies of adults receiving HAART have found increased peripheral and coronary artery disease. Children exposed to this therapy in utero are thus at an increased risk for toxicity and cardiac abnormalities, regardless of their HIV status. Preliminary studies have reported complications including lactic acidosis and mitochondrial toxicity, as well as cardiomyopathy. Further studies are needed to explore the long-term effects and possible toxicities of prophylactic antiretroviral therapy on infants born to HIV-infected mothers.",
keywords = "AIDS, Cardiomyopathy, Dyslipidemia, HAART, HIV, Mitochondrial toxicity, Prophylactic antiretroviral therapy.",
author = "Zareba, {Karolina M.} and Lavigne, {Jill E.} and Lipshultz, {Steven E}",
year = "2004",
month = "10",
day = "29",
doi = "10.1385/CT:4:3:271",
language = "English",
volume = "4",
pages = "271--279",
journal = "Cardiovascular Toxicology",
issn = "1530-7905",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Cardiovascular effects of HAART in infants and children of HIV-infected mothers

AU - Zareba, Karolina M.

AU - Lavigne, Jill E.

AU - Lipshultz, Steven E

PY - 2004/10/29

Y1 - 2004/10/29

N2 - Over the past decade, the course of human immunodeficiency virus (HIV) infection has been markedly altered by highly active antiretroviral therapy (HAART). As advances in early diagnosis and aggressive therapy, as well as better supportive care, become available to more HIV-infected patients, survival is being prolonged and more patients are experiencing cardiac abnormalities. Cardiovascular manifestations of pediatric HIV infection have especially proven to be an ongoing challenge to practicing physicians, who face cardiac abnormalities ranging from asymptomatic cardiomyopathy to severe heart failure. Antiretroviral therapy has substantially decreased vertical transmission of HIV; however, studies of adults receiving HAART have found increased peripheral and coronary artery disease. Children exposed to this therapy in utero are thus at an increased risk for toxicity and cardiac abnormalities, regardless of their HIV status. Preliminary studies have reported complications including lactic acidosis and mitochondrial toxicity, as well as cardiomyopathy. Further studies are needed to explore the long-term effects and possible toxicities of prophylactic antiretroviral therapy on infants born to HIV-infected mothers.

AB - Over the past decade, the course of human immunodeficiency virus (HIV) infection has been markedly altered by highly active antiretroviral therapy (HAART). As advances in early diagnosis and aggressive therapy, as well as better supportive care, become available to more HIV-infected patients, survival is being prolonged and more patients are experiencing cardiac abnormalities. Cardiovascular manifestations of pediatric HIV infection have especially proven to be an ongoing challenge to practicing physicians, who face cardiac abnormalities ranging from asymptomatic cardiomyopathy to severe heart failure. Antiretroviral therapy has substantially decreased vertical transmission of HIV; however, studies of adults receiving HAART have found increased peripheral and coronary artery disease. Children exposed to this therapy in utero are thus at an increased risk for toxicity and cardiac abnormalities, regardless of their HIV status. Preliminary studies have reported complications including lactic acidosis and mitochondrial toxicity, as well as cardiomyopathy. Further studies are needed to explore the long-term effects and possible toxicities of prophylactic antiretroviral therapy on infants born to HIV-infected mothers.

KW - AIDS

KW - Cardiomyopathy

KW - Dyslipidemia

KW - HAART

KW - HIV

KW - Mitochondrial toxicity

KW - Prophylactic antiretroviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=6044260105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044260105&partnerID=8YFLogxK

U2 - 10.1385/CT:4:3:271

DO - 10.1385/CT:4:3:271

M3 - Article

C2 - 15470274

AN - SCOPUS:6044260105

VL - 4

SP - 271

EP - 279

JO - Cardiovascular Toxicology

JF - Cardiovascular Toxicology

SN - 1530-7905

IS - 3

ER -